Quinolone inhibitors of lipoprotein-associated phospholipase A2

1. A method of treating a lipoprotein-associated phospholipase A2-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 38 are independently selected from the group consisting of hydrogen and deuterium; and

at least one of R 1 -R 38 is deuterium;

resulting in at least one effect selected from the group consisting of:

a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;

b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and

e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

2. The method as recited in claim 1 , further resulting in at least two effects selected from the group consisting of:

a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;

b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;

d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and

e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

3. The method as recited in claim 1 wherein said disorder is selected from the group consisting of coronary disorders, primary and secondary coronary disorders, acute coronary disorders, atherosclerosis, peripheral vascular atherosclerosis, cerebrovascular atherosclerosis, rheumatoid arthritis, diabetes, stroke, myocardial infarction, reperfusion injury, acute and chronic inflammation, psoriasis, and asthma.

4. The method as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of:

5. A method of treating a lipoprotein-associated phospholipase A2-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 38 are independently selected from the group consisting of hydrogen and deuterium; and

at least one of R 1 -R 38 is deuterium;

wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P 450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

6. The method as recited in claim 5 , wherein the cytochrome P 450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

7. The method as recited in claim 5 wherein said disorder is selected from the group consisting of coronary disorders, primary and secondary coronary disorders, acute coronary disorders, atherosclerosis, peripheral vascular atherosclerosis, cerebrovascular atherosclerosis, rheumatoid arthritis, diabetes, stroke, myocardial infarction, reperfusion injury, acute and chronic inflammation, psoriasis, and asthma.

8. The method as recited in claim 5 wherein said compound has a structural formula selected from the group consisting of:

9. A method of treating a lipoprotein-associated phospholipase A2-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 38 are independently selected from the group consisting of hydrogen and deuterium; and

at least one of R 1 -R 38 is deuterium;

wherein said compound is characterized by decreased inhibition of at least one cytochrome P 450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

10. The method as recited in claim 9 , wherein said cytochrome P 450 or monoamine oxidase isoform is selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAO A , and MAO B .

11. The method as recited in claim 9 wherein said disorder is selected from the group consisting of coronary disorders, primary and secondary coronary disorders, acute coronary disorders, atherosclerosis, peripheral vascular atherosclerosis, cerebrovascular atherosclerosis, rheumatoid arthritis, diabetes, stroke, myocardial infarction, reperfusion injury, acute and chronic inflammation, psoriasis, and asthma.

12. The method as recited in claim 9 wherein said compound has a structural formula selected from the group consisting of:

13. A method of treating a lipoprotein-associated phospholipase A2-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 38 are independently selected from the group consisting of hydrogen and deuterium; and

at least one of R 1 -R 38 is deuterium;

wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

14. The method as recited in claim 13 , wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST,” “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein.

15. The method as recited in claim 13 wherein said disorder is selected from the group consisting of coronary disorders, primary and secondary coronary disorders, acute coronary disorders, atherosclerosis, peripheral vascular atherosclerosis, cerebrovascular atherosclerosis, rheumatoid arthritis, diabetes, stroke, myocardial infarction, reperfusion injury, acute and chronic inflammation, psoriasis, and asthma.

16. The method as recited in claim 13 wherein said compound has a structural formula selected from the group consisting of: